bupivacaine has been researched along with Hemorrhage, Subarachnoid in 6 studies
Bupivacaine: A widely used local anesthetic agent.
1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide : A piperidinecarboxamide obtained by formal condensation of the carboxy group of N-butylpipecolic acid with the amino group of 2,6-dimethylaniline.
bupivacaine : A racemate composed of equimolar amounts of dextrobupivacaine and levobupivacaine. Used (in the form of its hydrochloride hydrate) as a local anaesthetic.
Excerpt | Relevance | Reference |
---|---|---|
"Cervical sympathetic block can relieve cerebral vasospasm after subarachnoid hemorrhage and increase NO content and NOS activity in plasma and cerebrospinal fluid to promote neural functional recovery." | 1.39 | Effect of cervical sympathetic block on cerebral vasospasm after subarachnoid hemorrhage in rabbits. ( Chun-jing, H; Guo-dong, L; Hao-xiong, N; Shan, O; Ya-ping, F; Yi-ran, L, 2013) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (16.67) | 18.2507 |
2000's | 3 (50.00) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Sánchez Arguiano, J | 1 |
Hernández-Hernández, MA | 1 |
Jáuregui Solórzano, RA | 1 |
Maldonado-Vega, S | 1 |
González Mandly, A | 1 |
Burón Mediavilla, J | 1 |
Chun-jing, H | 1 |
Shan, O | 1 |
Guo-dong, L | 1 |
Hao-xiong, N | 1 |
Yi-ran, L | 1 |
Ya-ping, F | 1 |
Treggiari, MM | 1 |
Romand, JA | 1 |
Martin, JB | 1 |
Reverdin, A | 1 |
Rüfenacht, DA | 1 |
de Tribolet, N | 1 |
Park, JH | 1 |
Shin, KM | 1 |
Hong, SJ | 1 |
Kim, IS | 1 |
Nam, SK | 1 |
Hans, GA | 1 |
Senard, M | 1 |
Ledoux, D | 1 |
Grayet, B | 1 |
Scholtes, F | 1 |
Creemers, E | 1 |
Lamy, ML | 1 |
Adachi, H | 1 |
Tashiro, T | 2 |
Goto, K | 1 |
Sadanaga, M | 1 |
Asai, S | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Cervical Sympathetic Block to Increase Cerebral Blood Flow in Patients With Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage[NCT05230134] | 10 participants (Anticipated) | Interventional | 2023-07-27 | Enrolling by invitation | |||
Stellate Ganglion Block for the Treatment of COVID-19-Induced Olfactory Dysfunction: A Prospective Pilot Study[NCT05445921] | Phase 1/Phase 2 | 20 participants (Actual) | Interventional | 2022-09-01 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"Participants will be asked to complete the ODOR, which is a patient-reported outcome measure assessing physical problems, functional limitations, and emotional consequences of olfactory dysfunction.~The ODOR has a minimum score of 0 and a maximum score of 112 with higher scores indicating a greater degree of impairment and limitation. The minimal clinically important difference is a change of 15 points." (NCT05445921)
Timeframe: baseline, 5-10 days post SGB #1, and 1 month
Intervention | score on a scale (Median) | ||
---|---|---|---|
ODOR at Baseline | ODOR at 1 Week | ODOR at 1 Month | |
Stellate Ganglion Block | 62 | 57 | 50.5 |
"Participants will complete the 40-item scratch and sniff UPSIT and mean change will be assessed.~The UPSIT has a minimum score of 0 and maximum score of 40 with lower scores indicating a greater degree of impairment. An UPSIT score of >33 for men and >34 for women is considered normosmic, and the minimal clinically important difference is a change of 4 points." (NCT05445921)
Timeframe: baseline, 5-10 days, and 1 month
Intervention | units on a scale (Median) | ||
---|---|---|---|
UPSIT at Baseline | UPSIT at 1 Week | UPSIT at 1 Month | |
Stellate Ganglion Block | 16.5 | 21 | 22.5 |
Participants will be asked about their change in olfactory dysfunction on a 7-point Likert scale from much better to much worse. (NCT05445921)
Timeframe: 5-10 days post SGB #1 and 1 month
Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CGI-I for Smell Loss at 1 Week71922197 | CGI-I for Smell Loss at 1 Month71922197 | CGI-I for Smell Distortion at 1 Week71922197 | CGI-I for Smell Distortion at 1 Month71922197 | CGI-I for Taste Loss at 1 Week71922197 | CGI-I for Taste Loss at 1 Month71922197 | CGI-I for Taste Distortion at 1 Week71922197 | CGI-I for Taste Distortion at 1 Month71922197 | |||||||||||||||||||||||||
About the Same | Slightly Better | Much Better | Moderately Better | |||||||||||||||||||||||||||||
Stellate Ganglion Block | 8 | |||||||||||||||||||||||||||||||
Stellate Ganglion Block | 10 | |||||||||||||||||||||||||||||||
Stellate Ganglion Block | 9 | |||||||||||||||||||||||||||||||
Stellate Ganglion Block | 11 | |||||||||||||||||||||||||||||||
Stellate Ganglion Block | 6 | |||||||||||||||||||||||||||||||
Stellate Ganglion Block | 1 | |||||||||||||||||||||||||||||||
Stellate Ganglion Block | 15 | |||||||||||||||||||||||||||||||
Stellate Ganglion Block | 4 | |||||||||||||||||||||||||||||||
Stellate Ganglion Block | 0 | |||||||||||||||||||||||||||||||
Stellate Ganglion Block | 14 | |||||||||||||||||||||||||||||||
Stellate Ganglion Block | 3 | |||||||||||||||||||||||||||||||
Stellate Ganglion Block | 2 | |||||||||||||||||||||||||||||||
Stellate Ganglion Block | 13 | |||||||||||||||||||||||||||||||
Stellate Ganglion Block | 12 | |||||||||||||||||||||||||||||||
Stellate Ganglion Block | 5 |
Participants will be asked about the severity of their olfactory dysfunction (and gustatory dysfunction) on a 5-point Likert scale from no smell loss to severe smell loss. (NCT05445921)
Timeframe: baseline, 5-10 days, and 1 month
Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CGI-S for Smell Loss at Baseline71922197 | CGI-S for Smell Loss at 1 Week71922197 | CGI-S for Smell Loss at 1 Month71922197 | CGI-S for Smell Distortion at Baseline71922197 | CGI-S for Smell Distortion at 1 Week71922197 | CGI-S for Smell Distortion at 1 Month71922197 | CGI-S for Taste Loss at Baseline71922197 | CGI-S for Taste Loss at 1 Week71922197 | CGI-S for Taste Loss at 1 Month71922197 | CGI-S for Taste Distortion at Baseline71922197 | CGI-S for Taste Distortion at 1 Week71922197 | CGI-S for Taste Distortion at 1 Month71922197 | |||||||||||||||||||||||||||||||||||||||||||||||||
No Problem | Very Mild Problem | Mild Problem | Moderate Problem | Severe Problem | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stellate Ganglion Block | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stellate Ganglion Block | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stellate Ganglion Block | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stellate Ganglion Block | 8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stellate Ganglion Block | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stellate Ganglion Block | 9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stellate Ganglion Block | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stellate Ganglion Block | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stellate Ganglion Block | 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stellate Ganglion Block | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stellate Ganglion Block | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stellate Ganglion Block | 11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stellate Ganglion Block | 6 |
1 trial available for bupivacaine and Hemorrhage, Subarachnoid
Article | Year |
---|---|
Cervical sympathetic block to reverse delayed ischemic neurological deficits after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Anesthetics, Local; Angiography, Digital Subtraction; Autonomic Nerve Block; Brain Ischemia; | 2003 |
Cervical sympathetic block to reverse delayed ischemic neurological deficits after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Anesthetics, Local; Angiography, Digital Subtraction; Autonomic Nerve Block; Brain Ischemia; | 2003 |
Cervical sympathetic block to reverse delayed ischemic neurological deficits after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Anesthetics, Local; Angiography, Digital Subtraction; Autonomic Nerve Block; Brain Ischemia; | 2003 |
Cervical sympathetic block to reverse delayed ischemic neurological deficits after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Anesthetics, Local; Angiography, Digital Subtraction; Autonomic Nerve Block; Brain Ischemia; | 2003 |
5 other studies available for bupivacaine and Hemorrhage, Subarachnoid
Article | Year |
---|---|
Stellate ganglion block as rescue therapy in refractory vasospasm after subarachnoid hemorrhage.
Topics: Anesthetics, Local; Aneurysm, Ruptured; Arm; Bupivacaine; Humans; Intracranial Aneurysm; Middle Aged | 2019 |
Effect of cervical sympathetic block on cerebral vasospasm after subarachnoid hemorrhage in rabbits.
Topics: Anesthetics, Local; Animals; Autonomic Nerve Block; Basilar Artery; Bupivacaine; Disease Models, Ani | 2013 |
Subacute spinal subarachnoid hematoma after spinal anesthesia that causes mild neurologic deterioration.
Topics: Anesthesia, Spinal; Anesthetics, Local; Bupivacaine; Female; Hematoma; Humans; Laminectomy; Low Back | 2007 |
Cerebral subarachnoid blood migration consecutive to a lumbar haematoma after spinal anaesthesia.
Topics: Aged; Anesthesia, Spinal; Anesthetics, Intravenous; Anesthetics, Local; Angioplasty, Balloon; Arteri | 2008 |
[Sudden decrease in the level of consciousness due to subarachnoid bleeding attack in a patient undergoing ophthalmic surgery under retrobulbar anesthesia].
Topics: Aged; Anesthesia, Local; Anesthetics, Local; Bupivacaine; Cataract Extraction; Consciousness Disorde | 1998 |